EcoDrugPlus

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSBGRG00000006201
Gene Symbol: NOD2
1 Cross references
167 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSBGRG00000015656
Gene Symbol: OPRD1
1 Cross references
254 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSBGRG00000004371
Gene Symbol: OPRM1
1 Cross references
215 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSBGRG00000012635
Gene Symbol: OPRL1
1 Cross references
202 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSBGRG00000007298
Gene Symbol: OXTR
1 Cross references
265 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSBGRG00000024897
Gene Symbol: PAK4
1 Cross references
160 Possible Orthologues:

Pancreatic Lipase

Ensembl ID : ENSBGRG00000016786
Gene Symbol: PNLIP
1 Cross references
301 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSBGRG00000013310
Gene Symbol: PTH1R
1 Cross references
199 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSBGRG00000001198
Gene Symbol: PPARA
1 Cross references
455 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSBGRG00000016651
Gene Symbol: PPARD
1 Cross references
420 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSBGRG00000003231
Gene Symbol: PIK3CA
1 Cross references
274 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSBGRG00000001650
Gene Symbol: PIK3CB
1 Cross references
216 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).